Sepsis Diagnostics Market Report 2026

The sepsis diagnostics market size has grown strongly in recent years. It will grow from $1.07 billion in 2025 to $1.16 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising hospital-acquired infections, adoption of rapid diagnostic tests, regulatory approvals, advanced lab infrastructure, increasing clinical awareness.

The sepsis diagnostics market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to AI-enabled diagnostic platforms, expansion of biomarker-based testing, tele-diagnostic integration, novel sepsis detection assays, growth of point-of-care diagnostics. Major trends in the forecast period include point-of-care diagnostic devices, biomarker-based tests, rapid blood culture kits, AI-assisted diagnostic platforms, integration with hospital IT systems.

The rising incidence of hospital-acquired infections is expected to drive the growth of the sepsis diagnostics market in the coming years. Hospital-acquired infections (HAIs) are infections that occur during or after a patient’s stay in a healthcare facility, typically 48 hours or more after admission, and were not present at the time of admission. The increase in HAIs is largely due to the rise of antibiotic resistance, which has developed from the overuse and misuse of antibiotics in healthcare settings, making infections more difficult to treat. Sepsis diagnostics play a critical role in detecting hospital-acquired infections early by identifying pathogens and biomarkers, allowing timely treatment and reducing complications. For example, in November 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2022-23, hospital-acquired complications (HACs) occurred in 2% of public hospital admissions and 0.8% of private hospital admissions, with healthcare-associated infections being the most frequent complication. Thus, the growing incidence of hospital-acquired infections is fueling the sepsis diagnostics market.

Key companies in the sepsis diagnostics market are developing innovative solutions, such as culture-free diagnostic platforms, to enable rapid and accurate detection of sepsis without relying on traditional blood cultures. Culture-free diagnostics detect pathogens or infections using advanced technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays, to identify pathogens directly from patient samples such as blood, saliva, or tissue. For instance, in April 2024, Deepull Diagnostics S.L., a Spain-based manufacturer, launched the UllCORE diagnostic system for early sepsis detection. The UllCORE system is a benchtop, culture-free multiplex PCR platform designed for rapid pathogen identification in sepsis and other acute infections. It extracts microbial DNA from 8 mL of whole blood and provides 50 reportable results within one hour, detecting 95% of sepsis-causing pathogens, including bacteria, fungi, and antibiotic resistance genes. Developed to improve early diagnosis and reduce antibiotic misuse, UllCORE supports hospitals in combating antimicrobial resistance.

In October 2024, Trinity Biotech plc, an Ireland-based medical laboratory company, acquired a 12.5% stake in Novus Diagnostics Ltd for $2.5 million. Through this acquisition, Trinity Biotech aims to accelerate the development and commercialization of Novus Diagnostics’ rapid point-of-care diagnostic solutions, including its 15-minute bloodstream infection test, to enhance sepsis diagnosis and patient outcomes. Novus Diagnostics Ltd., based in Ireland, develops rapid point-of-care diagnostic solutions for bloodstream infections, including sepsis.

Major companies operating in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMérieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., EKF Diagnostics Holdings plc, Boditech Med Inc., Alifax S.r.l., Abionic SA.

North America was the largest region in the sepsis diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sepsis diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have had a significant influence on the sepsis diagnostics market by raising the cost of imported instruments, blood culture media, assay kits, reagents, and advanced molecular diagnostic platforms. Hospitals, pathology laboratories, and research institutes in Asia-Pacific and emerging economies that depend on global suppliers have faced higher capital and operating costs, which can delay upgrades to automated and point-of-care diagnostic systems. These higher costs can slow the adoption of rapid and AI-enabled sepsis testing technologies. However, tariffs are also stimulating domestic production of diagnostic consumables and software platforms, supporting innovation and long-term supply chain resilience in the sepsis diagnostics market.

The sepsis diagnostics market research report is one of a series of new reports that provides sepsis diagnostics market statistics, including sepsis diagnostics industry global market size, regional shares, competitors with a sepsis diagnostics market share, detailed sepsis diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis diagnostics industry. This sepsis diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sepsis diagnostics encompass a variety of advanced technologies and tests designed to rapidly identify the presence of sepsis, a critical condition that can lead to organ failure and death if not treated promptly. These technologies help healthcare providers evaluate the severity of the condition and make timely, informed decisions to initiate appropriate treatment and improve patient outcomes.

The main products in sepsis diagnostics include instruments, blood culture media, assay kits and reagents, and software. Instruments are medical devices used to quickly analyze blood samples and detect pathogens, allowing for early and accurate identification of sepsis to enable timely treatment. Sepsis diagnostics employ technologies such as microbiology, molecular diagnostics, immunoassays, flow cytometry, and others to detect various pathogens, including bacterial, fungal, viral sepsis, and additional pathogens. Diagnostic methods include automated diagnostics and conventional diagnostics. These methods are utilized by a range of end-users, including hospitals and clinics, pathology and reference laboratories, and research institutes.

The sepsis diagnostics market consists of revenues earned by entities by providing services such as clinical consultation, rapid diagnostic testing solutions, point-of-care diagnostic solutions, biomarker testing, and molecular diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis diagnostics market also includes sales of sepsis diagnostic test kits, automated blood culture systems, molecular diagnostic equipment, sepsis biomarker assay kits, and rapid diagnostic devices for infection detection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.